On March 12, 2021, SinoBioPrint (Shanghai) Biotech Ltd. was honored to be invited to participate in the key project investor matchmaking meeting "Focus on Private Enterprises and Shared Development" held by Shanghai United Assets and Equity Exchange, and became the first roadshow project to preach .
At the beginning of the conference, SinoBioPrin founder and CEO Professor Chen Huimin took the stage as the first guest to give a project roadshow with the theme of "the last mile of the clinical application of bio-3D printing stem cell regenerative medicine". The company's growth history, the technical background of regenerative medicine, the company's self-developed stem cell and biological 3D printing technology platform, and five medical device clinical projects were introduced.
In the interactive communication session, Professor Chen Huimin answered the questions raised by the guests and conducted in-depth discussions among the entrepreneurs present at the meeting.
Q: Intellectual property protection of high-tech companies is an unavoidable obstacle. How does your company protect intellectual property rights?
Professor Chen: "Professional people do professional things. Our company uses a third-party intellectual property agency to apply for and warn us of some intellectual property rights. We mainly focus on research and development."
Question: In today's relatively impetuous social environment, how does your company cultivate talents, retain talents, stimulate talents to be motivated/creative, and concentrate on research and development?
Professor Chen: "First of all, improve the company's own development, so that employees have better development prospects and more opportunities for employees. Our company has an employee training plan, so that employees have the opportunity to further their studies after graduation."
At the same time, SinoBioPrin is also looking forward to cooperating with more companies, and can find more cooperation entry points in a wider range, deeper fields and higher levels, and discover new opportunities for cooperation. Investors are welcome to contact us and come to the company to exchange and learn.
With the encouragement and coordination of teachers from Shanghai Economic and Information Commission, Shanghai United Assets and Equity Exchange has listed SinoBioPrin as a non-public business for the clinical transformation of our cartilage 3D printing. For details, please click the following link: